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Abstract
Background—Although variants in the transcription factor 7-like 2 (TCF7L2) gene are
consistently associated with impaired fasting glucose (IFG) in Caucasians, data from large
population-based studies of African Americans are lacking. Moreover, few studies have
investigated the effects of TCF7L2 on IFG in the context of metabolic risk factors for diabetes.
Methods—We investigated the association between the TCF7L2 rs7903146 polymorphism and
incident IFG defined as fasting serum glucose levels of 100–125 mg/dl (5.6–6.9 mmol/l) in 1,377
African American and 5,152 Caucasian participants without diabetes and IFG at intake who
participated in the Atherosclerosis Risk in Communities (ARIC) Study in 1987–1989 and were
followed for 9 years.
Results—Incident IFG was identified in 810 (58.8%) African American and 2,652 (51.5%)
Caucasian participants. Compared to homozygous CC Caucasian individuals, heterozygous CT
[hazard ratio (HR) = 1.09 (95% CI=1.03–1.15)] and homozygous TT [1.18 (1.05–1.33)]
individuals had significantly higher risk of developing IFG over 9-year follow up. The association
between rs7903146 and IFG risk was stronger in Caucasians with obesity [HRCT vs. CC=1.28
(1.12, 1.47); HRTT vs. CC=1.65 (1.25, 2.17)] or high triglycerides [HRCT vs. CC=1.31(1.10, 1.56);
HRTT vs. CC=1.72 (1.21, 2.43)]. No association of the TCF7L2 rs7903146 polymorphism and
incident IFG was noted in African Americans.
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Conclusions—Our study replicates the association between rs7903146 and IFG risk in a
population-based, longitudinal cohort of Caucasians but not in African Americans. For the first
time, our study provides evidence for interactions between TCF7L2 and metabolic risk factors on
the occurrence of IFG in Caucasians.
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INTRODUCTION
Impaired fasting glucose (IFG), an intermediate stage between normoglycemia and diabetes,
is characterized by defects in insulin sensitivity and early-phase insulin secretion [1,2]. The
transcription factor 7-like 2 (TCF7L2) gene, a Wingless and Int (Wnt) signaling-associated
transcription factor located on chromosome 10q25, has emerged as a consistently replicated
susceptibility gene for type 2 diabetes and IFG [3,4,5,6,7]. In our previous work, we
demonstrated a significant association between the T allele at single nucleotide
polymorphism (SNP) rs7903146 and the risk of incident type 2 diabetes in middle-aged
African American and Caucasian participants of the Atherosclerosis Risk in Communities
(ARIC) Study[8]. The rs7903146 T allele has been described either as the causal risk variant
or the closest correlate to an unidentified functional variant [9], possibly impairing the
glucagon-like peptide-1-induced insulin secretion[10], but the exact mechanism is still under
investigation.
Although an effect of TCF7L2 on IFG has been observed in Caucasians [6,7], no studies of
TCF7L2 and prediabetes as quantified by incident IFG have been conducted in African
Americans. Moreover, potential TCF7L2 gene–metabolic risk factors interactions on IFG
have been largely unexplored.
Our previous work focused on the association between the rs7903146 SNP and type 2
diabetes[8]. In this study, we investigated whether the rs7903146 SNP of the TCF7L2 gene
is associated with incident IFG in a large community-based cohort of African-American and
Caucasian middle-aged adults in the ARIC Study. A second objective is to evaluate whether
the effect of the rs7903146 SNP on IFG varies by obesity and triglyceride levels.
MATERIALS AND METHODS
Study subjects and phenotype definitions
The ARIC Study is an ongoing, longitudinal cohort study of cardiovascular and other major
diseases among 15,792 men and women, aged 45 to 64 years old at baseline (1987–1989),
selected from 4 US communities: Forsyth County, NC; Jackson, MS; the northwestern
suburbs of Minneapolis, MN; and Washington County, MD. By design, African-Americans
were over-sampled at the Forsyth County site and were exclusively sampled in Jackson and
thus constituted 27% of the baseline cohort. Participants received an extensive examination,
including medical, social, and demographic data, and were reexamined every three years
with the first screen (baseline) occurring in 1987–89, the second in 1990–92, the third in
1993–95, and the fourth and last exam in 1996–98. The sampling procedures and methods
used in ARIC have been described in detail elsewhere[11].
We excluded ARIC participants who were not African-American or Caucasian (n=48),
African-Americans from Minnesota and Maryland field centers (n=55), participants with
prevalent diabetes at baseline or incident diabetes during follow-up (n=3,379), participants
with prevalent IFG at baseline (n=4,472), participants with missing genotype data or who
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did not provide consent for the use of their DNA (n=525), and participants with missing
information on incident IFG (n=784). Diabetes was defined as fasting serum glucose levels
of at least 7.0 mmol/L (126 mg/dl), nonfasting glucose levels of at least 11.1 mmol/L (200
mg/dl), current use of hypoglycemic medications (e.g., insulin or sulfonlyureas), or a self-
reported physician diagnosis of diabetes [2]. After these exclusions, 6,529 baseline
examination participants (1,377 African American and 5,152 Caucasians) were available for
analysis. The institutional review boards at all participating institutions approved the
procedures and all participants included in the analysis gave informed consent.
All covariates were measured at the baseline exam (visit 1). As a measure of prediabetes,
individuals with fasting serum glucose levels of 100–125 mg/dl (5.6–6.9 mmol/l)[2] were
classified as having IFG. Individuals without IFG at baseline who subsequently met this
criterion for incident IFG at visit 2, 3, or 4 were considered to be incident cases in the
analysis.
Self-reported cigarette smoking exposure was defined as ever smoking versus never
smoking obtained by a personal interview. Body mass index (BMI) was calculated as
measured weight (kg) divided by the square of measured height (m2). Individuals with a
BMI ≥30 kg/m2 were classified as obese[12]. Elevated waist circumference (WC) was
defined as WC≥102cm in males or WC≥88cm in females[13]. Blood pressure was measured
three times using a random zero sphygmomanometer and the average of the last two
measurements was used for this analysis. Hypertension was defined as systolic blood
pressure ≥ 140mmHg or diastolic blood pressure ≥ 90mmHg or a history of anti-
hypertension medication use[14]. Glucose was assessed by a modified hexokinase/
glucose-6-phosphate dehydrogenase procedure[15]. Plasma total cholesterol levels, high-
density lipoprotein cholesterol (HDL-C), and triglyceride levels were measured by
enzymatic methods. Low HDL-C was defined as less than 40 mg/dl in males and 50 mg/dl
in females. High triglyceride was defined as triglyceride levels higher than 200 mg/dl[16].
Insulin was measured by radioimmunoassay (125Insulin kit; Cambridge Medical Diagnosis,
Bilerica, MA). Physical activity was quantified using a slightly modified version of the
Baecke physical activity questionnaire[17], that classified work, sport and leisure activities
into categories ranging from 1 (low) to 5 (high).
SNP genotyping
The TCF7L2 rs7903146 SNP was genotyped by the ARIC Central Laboratory using
Taqman® assays (Applied Biosystems, Foster City, CA). Laboratory-designed probes were
obtained from Applied Bioystems and primers from IDT (Coralville, IA). All PCR reactions
took place in optical 384-well reaction plates (Applied Biosystems). Five percent of samples
were regenotyped for quality control and 726 ARIC participants were genotyped in
duplicate. The percent agreement between blind duplicates was 98% and the simple Kappa
coefficient was 0.97 indicating good genotyping quality.
Statistical analysis
All analyses were stratified by race to crudely account for population stratification. To
assess whether genotype distribution within each race departed from Hardy-Weinberg
equilibrium, a χ2 goodness-of-fit test was used. We estimated the predicted cumulative
incidence/risk of IFG over a 9-year follow-up under a semiparametric regression model. We
used Cox proportional hazards to estimate the hazard ratios (HRs) and 95% confidence
intervals (CIs) of incident IFG. The hazard function was formulated on the age scale and
date of onset of IFG was interpolated using blood glucose levels at the visits at each end of
the triennial intervals[18]. Furthermore, we assessed the association between IFG and
TCF7L2 using a more stringent definition of IFG, categorizing individuals with a fasting
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glucose value of 110 – 125 mg/dl as affected. Lastly, we evaluated the association between
rs7903146 and repeated fasting glucose values over 9 years of follow-up (visit 1–4) in the
ARIC study population using Generalized Estimating Equation models.
Covariates including history of ever smoking, BMI, obesity, hypertension, plasma HDL-C,
lipid medications, and history of work, sport, leisure time physical activity level were
assessed as potential confounders. We employed the change-in-estimate procedure[19] to
select confounders with a ≥10% change in the estimated HR required for retention in the
model. As all covariates assessed did not modify, or only slightly modified the estimated
effect of exposure, they were all removed from further analyses.
Following the published literature [4] and our findings from previous research [8], we
compared heterozygous CT-genotype and homozygous TT-genotype individuals to CC-
genotype individuals, using the rs7903146 CC-genotype as the referent group, and the T
allele as the risk variant. A variable taking on the values 0 for genotype CC, 1 for genotype
CT, and 2 for genotype TT was used to test for additive genetic effects.
Gene–environment interaction testing was assessed on the multiplicative and additive scales
between genotypes and different metabolic risk factors including obesity, elevated waist
circumference, hypertension, high triglycerides, and low HDL-C. With regard to
multiplicative interaction, variables were considered to be potential effect measure modifiers
if they departed from multiplicativity assessed by the Wald χ2 test for significance of the
estimated β-coefficient for the interaction term [20]. For additive interaction, variables were
considered as potential modifiers if departure from additivity was detected by the interaction
contrast ratio (ICR) [20,21]. ICRs were quantified as follows: ICR= HR_AB – HR_A –
HR_B + 1, where HR_AB represents the joint effect of metabolic exposure and the SNP,
and HR_A and HR_B represent the main effects of metabolic exposure and the SNP,
respectively[20]. Thus, ICR refers to the increased risk due to an additive interaction
between the metabolic risk factors and the T risk allele adjusted for age, gender, and study
center. Assuming an additive mode of inheritance, the ICR comparing TT to CT is equal to
the ICR comparing CT to CC when the metabolic exposure of interest is constant, thus only
one ICR was reported. Departures from zero suggest that the exposure of interest and the
SNP interact to cause IFG. The HR and the variance covariance matrix were used to
calculate ICR values and their 95% confidence intervals[21]. A p value <0.05 was
considered to indicate an important modifier for both multiplicative and additive interaction
assessments, despite the multiple tests as interaction tests tend to be underpowered [22].
Power analyses were performed using QUANTO 1.2 assuming unmatched case-control
study design [23]. Analysis was performed separately for Caucasians and African-
Americans, under an additive model and a two-sided p value of 0.05. We estimated 60% and
20% power to detect an odds ratio of 1.10 (CT vs. CC) in Caucasian and African-
Americans, respectively; for an odds ratio of 1.15, the power was estimated as 90% and
40%, respectively. However, because we estimated hazard ratios in the study and not odds
ratios, these power estimates were likely conservative.
RESULTS
The allele frequencies for rs7903146 in both races were in Hardy–Weinberg equilibrium
(p>0.05). Selected baseline characteristics of the ARIC Study participants by race and
genotype status are presented in Table 1. At the baseline exam, no significant differences in
demographic or behavioral characteristics (age, gender, leisure physical activity level, and
smoking) were noted by genotype status in Caucasian and African American ARIC
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participants. Moreover, no significant differences in hypertension, glucose, insulin, obesity
relate traits, triglycerides, and HDL-C were noted.
Over the course of 9 years of follow-up, incident IFG was identified in 810 (58.8%) African
American and 2,652 (51.5%) Caucasian ARIC participants (Table 2). The rs7903146 T
allele was observed with similar frequency in African-American and Caucasian individuals,
but was more common among incident IFG cases compared with non-cases in Caucasians
(Table 2). The rs7903146 T allele was significantly associated with incident IFG in
Caucasian participants [HRCT vs. CC (95% CIs)=1.09 (1.03, 1.15); HRTT vs. CC(95%
CIs)=1.18 (1.05, 1.33)], but not in African American participants [HRCT vs. CC (95%
CIs)=0.99 (0.89, 1.10); HRTT vs. CC (95% CIs)=0.98 (0.79, 1.22)] (Table 2).
To interrogate the consistency of our findings, we assessed the association between IFG and
TCF7L2 using a more stringent definition of IFG (110 – 125 mg/dl) and similar results were
obtained (data not shown). Lastly, a significant association between the rs7903146 T allele
and repeated fasting glucose across visit 1–4 was noted in Caucasians (β=0.2480 with
p=0.0389) but not in African Americans (β=0.3002 with p=0.2826), which is consistent with
the IFG findings.
We identified obesity and high triglyceride as important effect measure modifiers in
Caucasians, but no important modifiers were noted in African Americans (Table 3; Figure 1;
Online Appendix Table 1). Specifically, among non-obese Caucasians, heterozygous CT
[HR=1.07 (95% CI=1.00, 1.14)] and homozygous TT [1.14 (1.00, 1.30)] individuals had
slightly higher HRs (95%CI) of IFG over 9 years of follow-up compared to homozygous CC
individuals, whereas among obese Caucasians, heterozygous CT [1.28 (1.12, 1.47)] and
homozygous TT [1.65 (1.25, 2.17)] individuals had significantly higher HRs (95%CI) of
IFG compared to CC individuals (Figure 1; multiplicative interaction p value=0.01). Similar
results were obtained for high triglycerides. When each effect measure modifier was studied
separately, we observed a slightly larger ICR for obesity in Caucasians (Table 3), but testing
by bootstrapping did not find significant differences between ICRs for obesity and high
triglycerides[24].
DISCUSSION
TCF7L2 has been implicated as an important IFG susceptibility gene in different Caucasian
populations [6,7]. To our knowledge, our study is the first population-based study on the
TCF7L2 rs7903146 and prediabetes as measured by incident IFG in African Americans and
no association was noted. An earlier study in non-diabetic African American women (n=118
with 11 prevalent IFG cases) reported the lack of an association with prevalent IFG (effect
estimates not reported) [25], which is consistent with our findings. Our study replicates the
association between the T allele at rs7903146 and IFG risk in Caucasians, and for the first
time contributes evidence for interactions between TCF7L2 variants and obesity and high
triglycerides in Caucasians. Indeed, we demonstrate that the risk of developing IFG
associated with this TCF7L2 variant is substantially increased in the context of well known
metabolic risk factors for type 2 diabetes.
We and other investigators have previously demonstrated an association between the
TCF7L2 rs7903146 and type 2 diabetes in both races [3,4,8]. In this study, an association
with IFG was noted in Caucasians only. The majority of current literature suggests that
TCF7L2 is associated with impaired insulin secretion, but not with increased insulin
resistance [5,26,27]. In our previous study on TCF7L2 and type 2 diabetes in ARIC[8], we
found a slightly lower fasting insulin and homeostasis model assessment (HOMA) – insulin
resistance concentration among individuals with the T risk allele, suggestive of impaired
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insulin secretion. A possible explanation of our study findings is that TCF7L2 may impair
beta cell function, which when combined with insulin resistance caused by other factors
such as obesity provides a “double hit” that disproportionately increases the risk for IFG and
then type 2 diabetes. Given the number of analyses performed in this study, we applied a
crude Bonferroni correction (five potential effect measure modifiers and the full sample,
N=6), noting that such an approach is an over-correction because many of the analytic runs
assessed the same dependent variable. If such a correction were applied, the study results for
the additive interactions with obesity and high triglycerides remain statistically significant
although the association between TCF7L2 rs7903146 and IFG became non-significant,
which actually highlights the importance of our interaction analysis. Our study sample is a
group with fairly modest hyperglycaemia during 9 years of follow-up. The gradual rise in
fasting glucose with age may explain the modest effect observed between rs7903146 and
IFG, but the interactions with obesity and high triglycerides has beyond that (Table 3),
which highlights the importance of evaluating gene-metabolic risk factor interaction.
We observed an association between TCF7L2 rs7903146 and type 2 diabetes in our African
American sample[8], but did not observe an association with IFG in this study. The lack of
association within the African American may suggest that TCF7L2 rs7903146 primarily
impair the glucose metabolism through impaired glucose tolerance (IGT), which needs to be
tested by 2-hour postprandial glucose data. Unfortunately the ARIC Study does not have
sufficient data on 2-hour glucose (i.e. the data was only available at visit 4 and had very low
power to detect a modest effect). The lack of association may also reflect confounding by
unmeasured covariates that are differentially distributed in African American and Caucasian
participants, both of which warrant further investigation. Third, it is worth noting that the
limited power to detect such a modest effect in the African American sample (calculated as
20% for a relative risk of 1.10) may explain our findings as well.
Our data identified obesity and high triglycerides as significant effect measure modifiers in
Caucasians. When studied separately, the most prominent interaction with genotype was for
obesity (Table 3, Figure 1). To our knowledge, no interaction has been reported between
high triglycerides and rs7903146. A multiplicative interaction with obesity/high BMI on the
outcome of type 2 diabetes was observed in two previous studies by other investigators
[28,29]. Both studies found that the risk of type 2 diabetes increased in lean individuals
whereas no significant association was noted in obese/over-weight individuals, suggesting
that the SNP rs7903146 is a much more influential risk factor for lean individuals than for
obese individuals. However, in this current study and our previous publication in diabetes
[8], the effect in obese Caucasians appears slightly stronger than the effect in lean
Caucasians, which is discrepant from previous studies.
The differences in study populations (Caucasians vs. Japanese, men/women vs. men only),
analysis methods (additive vs. multiplicative interactions), study designs (cohort vs. case-
control, different inclusion/exclusion criteria) may explain these study discrepancies.
Although we are unable to elucidate the pathogenesis underlying the observed statistical
interactions, strong evidence indicates that abnormal metabolic traits including obesity and
dyslipidemia aggregate in diabetic patients and their relatives [30,31]. Genetic factors
interacting with shared and unique environmental factors may cause this aggregation of
metabolic traits [30]. Although our study has implicated, for the first time, interesting
relationships between these metabolic risk factors, the TCF7L2 variants and IFG in
Caucasians, the role of TCF7L2 variants in pathogenesis of IFG in the context of metabolic
risk factors remains to be determined.
Our study findings have public health significance of potential importance since they
suggest that having one or two rs7903146 T risk alleles only partially informs one’s risk for
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prediabetes, as quantified by IFG. In the Caucasian population, the risk of IFG conferred by
the T risk allele of rs7903146, even in the context of metabolic risk factors, only
demonstrated a modest risk. In the African American population, no association between the
T risk allele and IFG was noted. Thus, the cumulative risk of IFG likely depends on multiple
susceptibility variants, the gene-gene interactions, and most importantly, “established” risk
factors for type 2 diabetes such as BMI and other lifestyle habits.
In conclusion, our study replicates the association between the T allele at rs7903146 and
IFG risk in Caucasians, whereas no associations were observed in African Americans. Our
study provides new evidence for interactions between TCF7L2 and metabolic risk factors on
the risk of IFG in Caucasians, as was previously demonstrated for type 2 diabetes. The
reported differences between African American and Caucasian subpopulations require
replication in larger epidemiological studies, as we were underpowered to detect the very
modest effects that were observed in the Caucasians.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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